Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 October 2026

RegulatoryapprovedBovilis LumpyvaxPositive

AI Analysis

Summary

The Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion in exceptional circumstances for marketing authorisation of Bovilis Lumpyvax, a lumpy skin disease vaccine, during its October 6-8, 2026 meeting.

Outcome Details

Positive opinion adopted in exceptional circumstances for marketing authorisation

Importance:6/10

Sentiment:

0.80

CVMPveterinary medicinal productmarketing authorisationregulatory approvalexceptional circumstances

Read the original article

Published by EMA News on October 9, 2026 1:30 PM

Read Original